Progenics Pharma (PGNX) Misses Q3 EPS by 1c

Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $2.35 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts